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Abstract
The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein
belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found
in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia
(CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor
clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies
should help in prognosis assessment.
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Mutations in the ASXL1 (additional sex combs like 1)
gene were first reported in 2009 in myelodysplastic syn-
dromes [1]. ASXL1 maps to chromosome region 20q11,
close to the DNMT3B gene, and belongs to a family of
three paralogs. ASXL1 comprises 12 exons and is
expressed in most hematopoietic cell types.
Function of the ASXL1 protein
ASXL1 codes for a nuclear protein of 1084 residues
characterized by an N-terminal helix-turn-helix domain,
HARE-HTH [2], and an unusual C-terminal plant
homeodomain (PHD), which may bind methylated
lysines (Figure 1). The central part of ASXL1 contains
an ASXH globular domain that may interact with a
polycomb-associated deubiquitinase (DUB) [2,3]. ASXL1
regulates epigenetic marks and transcription through
interaction with polycomb complex proteins and various
transcription activators and repressors [3-5]. In Droso-
phila, ASX forms a complex with the ubiquitin carboxy-
terminal hydrolase calypso to constitute the recently
identified polycomb repressive deubiquitinase (PR-DUB)
complex [3,6]. Human wild-type ASXL1 associates with
the calypso ortholog BAP1 [7]. The calypso/BAP1 DUB
deubiquitylates K119ub on histone H2A, leading to gene
repression. However, the role of ASXL1 in leukemogen-
esis does not seem to be mediated by the DUB complex
[7]. Recent data have shown that ASXL1 interacts with
components of the polycomb complex PRC2, namely
EZH2 and SUZ12, two proteins involved in the deposi-
tion of H3K27me3 histone repressive marks. These two
PRC2 components are also mutated in myeloid malig-
nant diseases [8-11]. Inhibition of ASXL1 function leads
to loss of H3K27me3 histone marks. ASXL1 role could
be to recruit the PRC2 complex to known leukemogenic
loci such as HOXA genes [7]. ASXL1 also associates
with HP1a/CBX5, a component of the heterochromatin
repressive complex [6,12]. HP1a binds to histone H3.
JAK2 phosphorylates histone H3 and excludes HP1a
from chromatin [13]. Thus, a potential functional link
may exist between ASXL1 and JAK2 mutations but this
remains to be demonstrated.
The functions of the other ASXL proteins are poorly
defined. ASXL2 has been shown to regulate heart [14]
and bone development, as well as adipogenesis. Mouse
ASXL2 has been identified as a regulator of bone
mineral density and osteoclastogenesis [15] and whereas
ASXL1 represses, ASXL2 increases the expression of
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remain to be determined [17].
ASXL1 and concomitant mutations in myeloid
malignancies
The vast majority of the ASXL1 mutations found in
myeloid malignancies affect the twelfth exon of the gene
although rare mutations in other exons have been
detected [18]. ASXL1 mutations are frameshift and non-
sense mutations that are supposed to result in C-term-
inal truncation of the protein upstream of the PHD
finger (Figure 1). The functional relevance of some
reported missense mutations is not clear. The most fre-
quent mutation, which accounts for more than 50% of
all ASXL1 mutations, is a duplication of a guanine
nucleotide (c.1934dupG); it leads to a frameshift (p.
Gly646TrpfsX12). One study has described this muta-
tion as a PCR artefact [19], but because it is not found
in germ-line DNAs, controlD N A so ro t h e rs t u d i e d
types of cancers such as breast cancer, it is now gener-
ally considered to be a bona fide mutation.
ASXL1 mutations are usually heterozygous, suggesting
that haplo-insufficiency is the key pathological factor;
however, the truncated ASXL1 protein could also have a
dominant negative role in titrating out an interacting
protein. Actually, recent data have demonstrated a loss
of ASXL1 protein in leukemia samples with ASXL1
mutation, indicating that these mutations are loss-of-
function disease alleles [7].
ASXL1 is mutated in all types of malignant myeloid
diseases, including myelodysplastic syndromes (MDS),
myeloproliferative neoplasms (MPN), chronic myelomo-
n o c y t i cl e u k e m i a( C M M L )a n da c u t em y e l o i dl e u k e m i a
(AML). According to the series studied, ASXL1 muta-
tion frequency varies from a few percent to more than
50% of cases (Table 1). ASXL1 mutations are most
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Figure 1 Distribution of ASXL1 mutations along the protein. From top to bottom are shown the localization of the ASXL1 gene on
chromosome region 20q11, the exon structure of ASXL1, and the ASXL1 protein with its conserved motifs and binding regions: HARE helix-turn-
helix at the N-terminus, HP1/CBX5 binding region, ASXH, an a-helical domain that contains LXXLL (nuclear receptor boxes), and the C-terminal
plant homeodomain (PHD) finger. Below reported mutations (see Table 1) are shown along the protein: circles and triangles indicate frameshift
and nonsense mutations, respectively, and the colors correspond to the exon location.
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Page 2 of 6frequent in CMML (~ 45%). In MPNs, they are frequent
in primary myelofibrosis (PMF)(34.5%) and rare in poly-
cythemia vera (PV) or essential thrombocythemia (ET).
In AML, they are found in secondary (30%) rather than
in de novo cases (6.5%), and in AML with normal karyo-
type ASXL1 mutations are mutually exclusive with
NPM1 mutations [20]. ASXL1 is the second most fre-
quently mutated gene in MDSs after TET2 [21]. In
MDSs, ASXL1 mutations are more frequent in refractory
anemia with excess of blasts (RAEB) than in the other
f o r m ss u c ha sr e f r a c t o r ya n e m i aw i t hr i n gs i d e r o b l a s t s
(RARS) [1,5,22]. ASXL1 mutations are further detected
in rare cases of juvenile myelomonocytic leukemia
(JMML) [23] and in RARS-T [24].
With the exception of NPM1 and FLT3, it seems that
ASXL1 mutations coincide with mutations in many
known genes including EZH2 [18], IDH1/2, RUNX1 and
TET2 [21,22]. Although ASXL1 functions are related to
the PRC2 complex, which includes EZH2, ASXL1 and
EZH2 mutations are not mutually exclusive [18,38].
ASXL1 mutations can also cooperate with mutations in
genes encoding signaling (CBL, JAK2, NF1, RAS)a n d
splicing proteins (SF3B1, SRSF2, U2AF35). For example,
in MDSs, ASXL1 mutations are more frequent in
U2AF35-mutated patients than in U2AF35 wild-type
patients [39]. In MPNs, ASXL1 mutations are found
with the same frequency in JAK2V617F and JAK2 wild-
type cases [26,36]. In MDSs, ASXL1 mutations are often
associated with RUNX1 mutations, and, in AMLs, with
RUNX1 and CEBPA. [29,33,40].
Other alterations in ASXL1, ASXL2 and ASXL3
Few deletions of the gene have been reported and
ASXL1 is generally not included in the more telomeric
20q13 deletion that is often observed in myeloid dis-
eases. The ASXL1 gene can be translocated and fused to
the PAX5 gene in acute lymphoblastoid leukemia [41]
and altered by germ-line mutations in the Bohring-
Opitz syndrome; this severe syndrome leads to death at
an early age preventing to know whether susceptibility
to hematopoietic diseases might result from ASXL1
germ-line mutations [42]. In recent genome sequencing
studies rare mutations in ASXL1 and ASXL3 have also
been found in chronic lymphocytic leukemia [43] but
not in T-cell acute leukemia [44]. Mutations in ASXL2
and ASXL3 have not been found in myeloid diseases so
far, but ASXL2-MYST3 and EPC1-ASXL2 fusions have
been identified in myelodysplastic syndrome and T-cell
acute leukemia, respectively [45,46]. Both MYST3 and
EPC1 are epigenetic regulators and these fusion proteins
probably disrupt epigenetic protein complexes.
Animal models of ASXL1 loss
In a first model of Asxl1 gene knock-out in the mouse
ASXL1 loss mildly perturbed myelopoiesis but did not
trigger an actual hematological malignancy [47].
Table 1 Mutations in ASXL1 gene in published studies
Selected Ref. MDS
n (%)
CMML
n (%)
MPN
n (%)
Secondary AML
n (%)
De novo AML
n (%)
*Abdel-Wahab et al., [25] 12/63 (19.3)
*Abdel-Wahab et al., [18] 3/24 (12.5) 3/46 PMF (6.5)
Béjar et al., [21] 63/439 (14.4)
Brecqueville et al., [26] 17/149 (11.4): 6/30 PMF (20), 2/30 PV (7), 2/53 ET (4),
Boultwood et al., [5] 28/182 (15.4) 17/51 (33.3) 9/40 (22.5) 8/27 (29.6)
Boultwood et al., [27] +6/41 (CML) (14.6)
Carbuccia et al., [28] 5/64 (7.8)
Carbuccia et al., [20] 9/17 (58) 3/46 (6)
Chou et al., [29] 54/501 (10.8)
Gelsi-Boyer et al., [1] 4/35 (11.4) 17/39 (43.6)
Gelsi-Boyer et al., [30] 25/53 (47.2)
Grossmann et al., [31] 41/79 (52)
Jankowsa et al.,[32] 24/52 (46)
Pratcorona et al., [33] 3/24 (12.5) 35/775 (4.5)
Ricci et al.,[34] 23/42 PMF (54.8)
Rocquain et al., [22] 13/65 (20) 9/18 (50) 3/46 (6.5)
Shen et al., [35] 27/605 (4.5)
Stein et al., [36] 12/47 PMF (25.5)
1/42 PV (2)
Thol et al., [37] 40/193 (20.7)
Total* 148/914 (16.2) 124/274 (45) 41/119 PMF (34.5) 30/99 (30.3) 130/2000 (6.5)
* not included in final count because p.Gly646TrpfsX12 had not been taken into account; + including CML cases
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Page 3 of 6However, the effect of the absence of ASXL1 protein
may have been masked by partially penetrant perinatal
lethality. In another, more recent model of conditional
Asxl1 gene knock-out, the animals developed a strong
hematopoietic phenotype consistent with an MDS with
myeloproliferative features. In cooperation with NRAS
oncogenic mutation the absence of ASXL1 triggered an
MDS/MPN. These observations were confirmed by
experiments in hematopoietic cells using shRNA direc-
ted against ASXL1, which were highly coherent with the
expected role of ASXL1 in leukemogenesis [7].
ASXL1 mutations in disease evolution
Like TET2 mutations, ASXL1 mutations are found in
chronic and acute stages of myeloid malignancies. In a
study of MPNs, with the exception of a single patient who
acquired both ASXL1 and TET2 mutations, all patients
with ASXL1 mutation at leukemic transformation already
had ASXL1 mutation at the chronic stage [25]. In a series
of secondary AML with multilineage dysplasia we found
that in cases resulting from a transformation of a known
MDS the same ASXL1 mutation was present at both the
chronic and acute stages (Devillier et al., submitted).
These observations suggest that ASXL1 mutations may
constitute early hits in leukemogenesis and precede other
alterations such as JAK2 and TET2 mutations [24,25,28].
However, there is also evidence to suggest that the oppo-
site is true in some cases. In MPNs, for example, the pro-
portion of ASXL1 mutations is higher in post-PV
m y e l o f i b r o s i s( M F )a n dp o s t - E TM Ft h a ni nP Va n dE T .
This suggests that the ASXL1 mutation may follow a JAK2
mutation and could therefore help predict the risk of evo-
lution from PV and ET to MF [26,36,48]. As such, ASXL1
mutations may play a crucial role in the pathogenesis of
PMF, as well as in the molecular progression from the
c h r o n i cp h a s eo fap r e v i o u sP Vo rE Tt oM F .F i n a l l y ,i n
MDSs and CMML, ASXL1 mutations seem to be present
in chronic phases and precede transformation and in rare
cases, ASXL1 mutations can be lost or acquired during
relapse of de novo AML [29].
ASXL1 mutations in disease outcome
A number of studies have linked ASXL1 mutations to the
outcome of malignant myeloid diseases. In a study of
MPNs based on the DIPSS-plus score [49] (Dynamic
International Prognostic Scoring System for primary mye-
lofibrosis), ASXL1 mutation tended to be associated with
an aggressive disease and a poor overall survival [26]. In a
large study of PMF patients ASXL1 mutations were asso-
ciated with shorter overall survival [50]. In CMML, the
presence of an ASXL1 mutation could help predict trans-
f o r m a t i o nt oA M L[ 3 0 ] .I nM D S s ,ASXL1 mutations are
associated with a reduced time to progression in AML and
constitute an independent prognostic marker [37]. Finally,
a study of 18 genes in a large cohort of MDSs showed that
mutations in 5 genes had prognostic impact: TP53, EZH2,
ETV6, RUNX1 and ASXL1 [21]. Coupled with the standar-
dized international prognostic scoring system (IPSS),
mutations in these five genes could help refine the prog-
nosis evaluation of MDSs.
By contrast, a study of a large cohort of 605 AML cases
without cytogenetic prognostic markers other than 11q23
abnormalities, reported that ASXL1 mutations were not
associated with outcome [35]. However, they were asso-
ciated with shorter overall survival in patients with inter-
mediate-risk AML [29,33]. A recent study of 476 cases
with intermediate-risk de novo AML showed that ASXL1
mutations have a major impact on outcome [51]. Accord-
ing to the current European LeukemiaNet (ELN) guide-
lines for the diagnosis and management of AML, AMLs
with normal karyotype are classified into two genetic cate-
gories based on their NPM1, FLT3-ITD and CEBPA muta-
tion status: the ELN Favorable category is defined as
mutated CEBPA and/or mutated NPM1 without FLT3-IT;
all remaining cases (ie, those with wild-type CEBPA,a n d
wild-type NPM1 with or without FLT3-ITD or mutated
NPM1 with FLT3-ITD) form the ELN Intermediate-I cate-
gory [52,53]. ASXL1 mutations have been associated with
inferior survival among ELN Favorable, but not among
ELN Intermediate-I patients [40]. Taken together, these
data show that ASXL1 mutations have prognostic value in
certain subgroups of AML patients.
Conclusion
In almost all studies, and whatever the type of myeloid
malignancy, ASXL1 mutations are associated with
adverse features including, but not limited to myelodys-
plasia, myelofibrosis or progression to AML. Systematic
detection of ASXL1 mutations could thus help in the
assessment of disease and should perhaps be implemen-
ted in routine practice, whether associated with already
systematically-surveyed mutations (CEBPA, JAK2, FLT3,
NPM1) or in upcoming systematic genome analyses.
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